Search

Your search keyword '"Cobo S"' showing total 15 results
Start Over Author "Cobo S" Publisher elsevier b.v.
15 results on '"Cobo S"'

1. 261P Subtyping of residual disease (RD) following neoadjuvant chemotherapy (NACT) for triple negative breast cancer (TNBC): Evolution and prognostic impact.

Author

Diaz-Guardamino, I. Echavarria, Lopez-Tarruella Cobo, S., Del Monte-Millan, M., Alvarez, E., Gilarranz, Y. Jerez, Anton, F. Moreno, Saenz, J.Á. García, Massarrah, T., Ocaña, I., Cebollero, M., Garcia, A.I. Ballesteros, Sarmiento, U. Bohn, Gomez, H., Rivera, H. Fuentes, Lopez, B. Herrero, Polo, C., Bueno, O., Rahimi, P., Muiño, C. Bueno, and Jimenez, M. Martin

Subjects
*TRIPLE-negative breast cancer, *NEOADJUVANT chemotherapy
Published
2024
Full Text
View/download PDF

2. 942 - The chemokine IP10 (CXCL10) dominates the long-term immune response stimulated by BCG treatment of non-muscle invasive bladder cancer, but a high concentration of IP10 in urine is strongly indicative of risk for the development of intolerance to BCG

Author

Alvarez Maestro, M.E., Ashiru, O., Esteso, G., Garcia-Cuesta, E.M., Lopez-Cobo, S., Alvarez-Maestro, M., Linares, A., Leibar, A., Gomez-Rivas, J., Ho, M.M., Martinez-Pineiro, L., and Valés-Gómez, M.

Published
2018
Full Text
View/download PDF

5. 141MO Pathological response and early survival data according to TNBCtype4 classifier in operable triple-negative breast cancer (TNBC) treated with neoadjuvant carboplatin and docetaxel.

Author

Echavarria Diaz-Guardamino, I., Lopez-Tarruella Cobo, S., Del Monte-Millan, M., Alvarez, E., Jerez, Y., Moreno Anton, F., García Saenz, J.Á., Massarrah, T., Ocaña, I., Cebollero, M., Ballesteros Garcia, A.I., Bohn Sarmiento, U., Gomez, H., Fuentes, H.A., Herrero Lopez, B., Gamez Casado, S., Bueno, O., Jiménez-Santos, M.J., Roche-Molina, M., and Martin Jimenez, M.

Subjects
*TRIPLE-negative breast cancer, *DOCETAXEL, *CARBOPLATIN
Published
2022
Full Text
View/download PDF

6. TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy.

Author

Martín, M., Stecklein, S.R., Gluz, O., Villacampa, G., Monte-Millán, M., Nitz, U., Cobo, S., Christgen, M., Brasó-Maristany, F., Álvarez, E.L., Echavarría, I., Conte, B., Kuemmel, S., Bueno-Muiño, C., Jerez, Y., Kates, R., Cebollero, M., Kolberg-Liedtke, C., Bueno, O., and García-Saenz, J.Á.

Subjects
*PATHOLOGIC complete response, *TRIPLE-negative breast cancer, *DISEASE risk factors, *GENE regulatory networks, *BREAST cancer, *TUMOR classification
Abstract

Identification of biomarkers to optimize treatment strategies for early-stage triple-negative breast cancer (TNBC) is crucial. This study presents the development and validation of TNBC-DX, a novel test aimed at predicting both short- and long-term outcomes in early-stage TNBC. The objective of this study was to evaluate the association between TNBC-DX and efficacy outcomes [pathologic complete response (pCR), distant disease-free survival (DDFS) or event-free survival (EFS), and overall survival (OS)] in the validation cohorts. Information from 1259 patients with early-stage TNBC (SCAN-B, CALGB-40603, and BrighTNess) was used to establish the TNBC-DX scores. Independent validation of TNBC-DX was carried out in three studies: (i) WSG-ADAPT-TN; (ii) MMJ-CAR-2014-01; and (iii) NeoPACT, including 527 patients with stage I-III TNBC undergoing neoadjuvant chemotherapy. In WSG-ADAPT-TN, patients were randomized to receive nab-paclitaxel plus gemcitabine or carboplatin. In MMJ-CAR-2014-01, patients received carboplatin plus docetaxel. In NeoPACT, patients received carboplatin plus docetaxel and pembrolizumab. TNBC-DX test was created incorporating the 10-gene Core Immune Gene module, the 4-gene tumor cell proliferation signature, tumor size, and nodal staging. In the two independent validation cohorts without pembrolizumab, the TNBC-DX pCR score was significantly associated with pCR after adjustment for clinicopathological variables and treatment regimen [odds ratio per 10-unit increment 1.34, 95% confidence interval (CI) 1.20-1.52, P < 0.001]. pCR rates for the TNBC-DX pCR-high, pCR-medium, and pCR-low categories were 56.3%, 53.6%, and 22.5% respectively (odds ratio for pCR-high versus pCR-low 3.48, 95% CI 1.72-7.15, P < 0.001). In addition, the TNBC-DX risk score was significantly associated with DDFS [hazard ratio (HR) high-risk versus low-risk 0.24, 95% CI 0.15-0.41, P < 0.001] and OS (HR 0.19, 95% CI 0.11-0.35, P < 0.001). In the validation cohort with pembrolizumab, the TNBC-DX scores were significantly associated with pCR, EFS, and OS. TNBC-DX predicts pCR to neoadjuvant taxane–carboplatin in stage I-III TNBC and helps to forecast the patient's long-term survival in the absence of neoadjuvant anthracycline–cyclophosphamide, and independent of pembrolizumab use. • TNBC-DX is a novel genomic test designed for patients with newly diagnosed stage I-III TNBC. • The assay integrates tumor and nodal staging with immune and proliferation signatures. • The TNBC-DX pCR score was found to be significantly associated with pCR after adjustment for clinical variables and treatment. • The TNBC-DX risk score identifies patients with lower or higher risk of recurrence irrespective of pCR status and pembrolizumab use. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

7. 237MO TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy without immunotherapy.

Author

Jimenez, M. Martin, Gluz, O., Villacampa, G., Lopez-Tarruella Cobo, S., Nitz, U.A., Cobo, S., Brasó-Maristany, F., Christgen, M., Gilarranz, Y. Jerez, Kummel, S., Conte, B., Diaz-Guardamino, I. Echavarria, Graeser-Mayer, M.K., Kreipe, H., Del Monte-Millan, M., Lopez, B. Herrero, Perou, C.M., Brunet, L. Pare, Prat, A., and Harbeck, N.

Subjects
*TRIPLE-negative breast cancer, *NEOADJUVANT chemotherapy, *IMMUNOTHERAPY
Published
2024
Full Text
View/download PDF

11. 281P Prevalence of HER2-low breast cancer in the GEICAM/2011-06 trial: Agreement in HER2-low classification between standardized immunohistochemistry assays.

Author

Rojo, F., Calvo-Martinez, L., B. bermejo, Bernet, L., Burgués, O., García-Caballero, T., Lopez-Tarruella Cobo, S., Pérez, S., Antolín-Novoa, S., Cejalvo, J.M., Gilarranz, Y. Jerez, Estevez, C. Morales, Rendo, C. Reboredo, Martinez, M.T.M., Herranz, J., Sánchez, R. Rincón, Caballero, R., Barnadas, A., De la Haba Rodriguez, J., and Jimenez, M. Martin

Subjects
*BREAST cancer, *IMMUNOHISTOCHEMISTRY, *CLASSIFICATION
Published
2024
Full Text
View/download PDF

12. 258P Correlation between pathological complete response (pCR) following neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) with or without pertuzumab (TCHP) and PAM50 subtypes in HER2(+) early breast cancer (eBC).

Author

Muiño, C. Bueno, Diaz-Guardamino, I. Echavarria, Alvarez, E., Gilarranz, Y. Jerez, Lopez, B. Herrero, Del Monte, M., Massarrah, T., Cebollero, M., Nevado, M., Barrio, P.D.L.M. de la Morena, Ayala de la Pena, F., Saenz, J.Á. García, Anton, F. Moreno, Rodriguez, A., Verduguez, T. Quintanar, Gimenez, D. Malon, Garcia, A.I. Ballesteros, Bañón, D., Lopez-Tarruella Cobo, S., and Jimenez, M. Martin

Subjects
*DOCETAXEL, *BREAST cancer, *TRASTUZUMAB, *CARBOPLATIN
Published
2024
Full Text
View/download PDF

13. 233P Germline genetic testing before formal counseling: Impact in cancer management in a Spanish university hospital.

Author

Bringas Beranek, M., Echavarria Diaz-Guardamino, I., Polo, C., Flores Sanchez, C., Munoz Martin, A.J., Ortega Morán, L., Herrero Lopez, B., Calvo Ferrandiz, P.A., Jerez Gilarranz, Y., Torres Perez-Solero, G., Lopez-Tarruella Cobo, S., Gamez Casado, S., Perez Ramirez, S., Veiga Fernández, A., Pajares, J.A., Sanz, M., Suarez, J., Del Monte-Millan, M., Martin Jimenez, M., and Marquez-Rodas, I.

Subjects
*GENETIC testing, *UNIVERSITY hospitals, *GERM cells, *COUNSELING
Published
2023
Full Text
View/download PDF

14. Generation and molecular characterization of a monoclonal antibody reactive with conserved epitope in sphingomyelinases D from Loxosceles spider venoms.

Author

Dias-Lopes, C., Felicori, L., Rubrecht, L., Cobo, S., Molina, L., Nguyen, C., Galéa, P., Granier, C., Molina, F., and Chávez-Olortegui, C.

Subjects
*MONOCLONAL antibodies, *EPITOPES, *SPHINGOMYELINASE, *LOXOSCELES, *SPIDER venom, *RECOMBINANT proteins, *IMMUNOASSAY
Abstract

Highlights: [•] A monoclonal antibody (LiD1mAb16) against a recombinant SMase D isoform was produced. [•] LiD1mAb16 was cross-reactive with protein spots from different Loxosceles species. [•] LiD1mAb16 recognizes a linear epitope in the catalytic loop of SMases D. [•] LiD1mAb16 showed neutralizing potential. [•] This mAb is a candidate for therapeutic serum development or immunodiagnostic assays. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results